Addressing the challenges of adherence

被引:176
作者
Bartlett, JA [1 ]
机构
[1] Duke Univ, Med Ctr, Dept Infect Dis, Durham, NC 27710 USA
关键词
adherence; AIDS; antiretroviral therapy; compliance; HIV;
D O I
10.1097/00126334-200202011-00002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Adherence to antiretroviral therapy is a crucial determinant of treatment success. Studies have unequivocally demonstrated the close association between adherence and plasma HIV RNA levels, CD4 cell counts, and mortality in patients with HIV infection and disease. Adherence levels of greater than or equal to95% are required to maintain virologic suppression. However, actual adherence rates are often far lower; most studies show that 40% to 60% of patients are <90% adherent. Adherence also tends to decrease over time. Patients offer a range of reasons for nonadherence, but the most frequently cited one is simply that they forget; other reasons include being away from home, being busy, or experiencing a change in daily routine. Additional barriers to adherence include psychiatric disorders, such as depression or substance use, uncertainty about the effectiveness of treatment and the consequences of poor adherence, regimen complexity, and treatment side effects. Several strategies can be employed in the effort to support patients' adherence. and all members of the multidisciplinary team should ideally employ these strategies in combination. Efforts should be made to educate and motivate patients, simplify treatment regimens and tailor them to individual lifestyles, prepare for and manage side effects, and address the concrete issues that may be a barrier to adherence. Recruiting an adherence monitor, providing memory aids to medication taking, and anticipating course corrections can also help patients achieve the adherence rates needed for successful treatment of HIV infection and disease.
引用
收藏
页码:S2 / S10
页数:9
相关论文
共 28 条
  • [1] ARNSTEN J, 2000, 7 C RETR OPP INF SAN
  • [2] Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population
    Bangsberg, DR
    Hecht, FM
    Charlebois, ED
    Zolopa, AR
    Holodniy, M
    Sheiner, L
    Bamberger, JD
    Chesney, MA
    Moss, A
    [J]. AIDS, 2000, 14 (04) : 357 - 366
  • [3] Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults
    Bartlett, JA
    DeMasi, R
    Quinn, J
    Moxham, C
    Rousseau, F
    [J]. AIDS, 2001, 15 (11) : 1369 - 1377
  • [4] Management of the adverse effects of antiretroviral therapy and medication adherence
    Blake, M
    Sherer, R
    [J]. CLINICAL INFECTIOUS DISEASES, 2000, 30 : S96 - S116
  • [5] Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG Adherence Instruments
    Chesney, MA
    Ickovics, JR
    Chambers, DB
    Gifford, AL
    Neidig, J
    Zwickl, B
    Wu, AW
    [J]. AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2000, 12 (03): : 255 - 266
  • [6] Cramer J.A., 1995, AM J MANAG CARE, V1, P45
  • [7] Adherence to antiretroviral and Pneumocystis prophylaxis in HIV disease
    Eldred, LJ
    Wu, AW
    Chaisson, RE
    Moore, RD
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1998, 18 (02) : 117 - 125
  • [8] Friedland GH, 1999, AIDS, V13, pS61
  • [9] Gallant J E, 1998, J Int Assoc Physicians AIDS Care, V4, P32
  • [10] Sociodemographic and psychological variables influencing adherence to antiretroviral therapy
    Gordillo, V
    del Amo, J
    Soriano, V
    González-Lahoz, J
    [J]. AIDS, 1999, 13 (13) : 1763 - 1769